Trial Profile
A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Dose-escalation, Phase 1 Trial of Anti-IL-20 in Subjects With Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Feb 2017
Price :
$35
*
At a glance
- Drugs Fletikumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
- 09 Dec 2010 Actual patient number is 16 as reported by ClinicalTrials.gov.
- 09 Dec 2010 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.